Skip to main content
Top
Published in: European Journal of Pediatrics 7/2020

01-07-2020 | Insulins | Original Article

Urinary C-peptide creatinine ratio to differentiate type 2 diabetes mellitus from type 1 in pediatric patients

Authors: Wafaa Elzahar, Ahmed Arafa, Amira Youssef, Adel Erfan, Doaa El Amrousy

Published in: European Journal of Pediatrics | Issue 7/2020

Login to get access

Abstract

Type 2 diabetes mellitus (T2DM) is frequently misdiagnosed in children and treated as type 1 DM (T1DM) with insulin. Urinary C-peptide to creatinine ratio (UCPCR) can be used to measure ß cell function and endogenous insulin. We aimed to assess the value of UCPCR to differentiate T2DM from T1DM in pediatric patients. We assessed UCPCR from urine sample taken 2 h after lunch in 50 children with T1DM and 30 children with T2DM (duration of the disease ≥ 2 years and without renal impairment). Fasting and postprandial C-peptide levels were also evaluated in all included children. Receiver operating characteristic (ROC) curve was performed to assess the optimal UCPCR cutoff level to differentiate T2DM from T1DM in children. UCPCR was significantly lower in children with T1DM compared with those with T2DM (P < 0.001). There was a significant positive correlation between UCPCR and fasting C-peptide, postprandial C-peptide, and age of onset. There was a significant negative correlation between the UCPCR and both HbA1c and duration of DM in T1DM. Fasting C-peptide had a sensitivity of 63%, a specificity of 84% at a cutoff point ≥ 1.3 ng/ml to differentiate T2DM from T1DM. Postprandial C-peptide had a sensitivity of 87%, a specificity of 86% at a cutoff point ≥ 3.2 ng/ml to differentiate T2DM from T1DM. Finally, UCPCR had a sensitivity of 97%, a specificity of 88% at a cutoff point ≥ 0.28 nmol/nmol to differentiate T2DM from T1DM in pediatric patients.
Conclusion: UCPCR is an easy noninvasive reliable marker to differentiate T2DM from T1DM in pediatric patients.
What is Known:
• Type 2 DM (T2DM) is frequently misdiagnosed in children and treated as type 1 DM (T1DM) with insulin.
• Urinary C-peptide to creatinine ratio (UCPCR) can be used to measure ß cell function and endogenous insulin.
What is New:
• We revealed that UCPCR had a sensitivity of 97%, a specificity of 88% at a cutoff point ≥ 0.28 nmol/nmol to differentiate T2DM from T1DM.
• UCPCR is an easy noninvasive dependable marker to diagnose T2DM from T1DM in pediatric patients.
Literature
1.
go back to reference Mayer-Davis EJ, Kahkoska AR, Jefferies C, Dabelea D, Balde N, Gong CX, Aschner P, Craig ME (2018) ISPAD Clinical Practice Consensus Guidelines 2018: definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes 19(Suppl 27):7CrossRef Mayer-Davis EJ, Kahkoska AR, Jefferies C, Dabelea D, Balde N, Gong CX, Aschner P, Craig ME (2018) ISPAD Clinical Practice Consensus Guidelines 2018: definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes 19(Suppl 27):7CrossRef
2.
go back to reference Hanna XU, Verre MC (2018) Type 2 diabetes mellitus in children. Am Fam Physician 98(9):590–594 Hanna XU, Verre MC (2018) Type 2 diabetes mellitus in children. Am Fam Physician 98(9):590–594
3.
go back to reference Craig ME, Jefferies C, Dabelea D, Balde N, Seth A, Donaghue KC (2014) Definition, epidemiology and classification of diabetes in children and adolescents. Pediatr Diabetes 15(S20):4–17CrossRef Craig ME, Jefferies C, Dabelea D, Balde N, Seth A, Donaghue KC (2014) Definition, epidemiology and classification of diabetes in children and adolescents. Pediatr Diabetes 15(S20):4–17CrossRef
4.
go back to reference Leighton E, Sainsbury CAR, Jones GC (2017) A practical review of C-peptide testing in diabetes. Diabetes Ther 8(3):475–487CrossRef Leighton E, Sainsbury CAR, Jones GC (2017) A practical review of C-peptide testing in diabetes. Diabetes Ther 8(3):475–487CrossRef
5.
go back to reference Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG (2016) Random non-fasting C–peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabet Med 33:1554–1558CrossRef Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG (2016) Random non-fasting C–peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabet Med 33:1554–1558CrossRef
6.
go back to reference Ludvigsson J, Carlsson A, Forsander G, Ivarsson I, Kockum I, Lernmark A, Lindblad B, Marcus C, Samuelsson U (2012) C-peptide in classification of diabetes in children and adolescents. Pediatr Diabetes 13(1):45–50CrossRef Ludvigsson J, Carlsson A, Forsander G, Ivarsson I, Kockum I, Lernmark A, Lindblad B, Marcus C, Samuelsson U (2012) C-peptide in classification of diabetes in children and adolescents. Pediatr Diabetes 13(1):45–50CrossRef
7.
go back to reference Jones AG, Hattersley AT (2013) The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 30:803–817CrossRef Jones AG, Hattersley AT (2013) The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 30:803–817CrossRef
8.
go back to reference Besser RE (2013) Determination of C-peptide in children: when is it useful? Pediatr Endocrinol Rev 10:494–502PubMed Besser RE (2013) Determination of C-peptide in children: when is it useful? Pediatr Endocrinol Rev 10:494–502PubMed
9.
go back to reference Jones AG, Besser RE, McDonald TJ, Shields BM, Hope SV, Bowman P, Oram RA, Knight BA, Hattersley AT (2011) Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes. Diabet Med 28:1034–1038CrossRef Jones AG, Besser RE, McDonald TJ, Shields BM, Hope SV, Bowman P, Oram RA, Knight BA, Hattersley AT (2011) Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes. Diabet Med 28:1034–1038CrossRef
10.
go back to reference McDonald TJ, Knight BA, Shields BM, Bowman P, Salzmann MB, Hattersley AT (2009) Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clin Chem 55:2035–2039CrossRef McDonald TJ, Knight BA, Shields BM, Bowman P, Salzmann MB, Hattersley AT (2009) Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clin Chem 55:2035–2039CrossRef
11.
go back to reference Kuhtreiber WM, Washer SLL, Hsu E, Zhao M, Reinhold P, Burger D, Zheng H, Faustman DL (2015) Low levels of C-peptide have clinical significance for established type 1 diabetes. Diabet Med 32(10):1346–1353CrossRef Kuhtreiber WM, Washer SLL, Hsu E, Zhao M, Reinhold P, Burger D, Zheng H, Faustman DL (2015) Low levels of C-peptide have clinical significance for established type 1 diabetes. Diabet Med 32(10):1346–1353CrossRef
12.
go back to reference Cho MJ, Kim MS, Kim CJ, Kim EY, Kim JD, Kim EY, Lee DY (2014) Fasting serum C-peptide is useful for initial classification of diabetes mellitus in children and adolescents. Ann Pediatr Endocrinol Metab 19(2):80–85CrossRef Cho MJ, Kim MS, Kim CJ, Kim EY, Kim JD, Kim EY, Lee DY (2014) Fasting serum C-peptide is useful for initial classification of diabetes mellitus in children and adolescents. Ann Pediatr Endocrinol Metab 19(2):80–85CrossRef
13.
go back to reference D’Adamo E, Caprio S (2011) Type 2 diabetes in youth: epidemiology and pathophysiology. Diabetes Care 34(S2):S161–S165CrossRef D’Adamo E, Caprio S (2011) Type 2 diabetes in youth: epidemiology and pathophysiology. Diabetes Care 34(S2):S161–S165CrossRef
14.
go back to reference Wahren J, Kallas A, Sima AA (2012) The clinical potential of C-peptide replacement in type 1 diabetes. Diabetes 61:761–772CrossRef Wahren J, Kallas A, Sima AA (2012) The clinical potential of C-peptide replacement in type 1 diabetes. Diabetes 61:761–772CrossRef
15.
go back to reference Besser REJ, Shields BM, Hammersley SE, Colclough K, McDonald TJ, Gray Z, Heywood JJN, Barrett TG, Hattersley AT (2013) Home urine C-peptide creatinine ratio testing can identify type 2 and MODY in pediatric diabetes. Pediatr Diabetes 14(3):181–188PubMed Besser REJ, Shields BM, Hammersley SE, Colclough K, McDonald TJ, Gray Z, Heywood JJN, Barrett TG, Hattersley AT (2013) Home urine C-peptide creatinine ratio testing can identify type 2 and MODY in pediatric diabetes. Pediatr Diabetes 14(3):181–188PubMed
16.
go back to reference Besser REJ, Ludvigsson J, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2011) Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care 34:607–609CrossRef Besser REJ, Ludvigsson J, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2011) Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care 34:607–609CrossRef
17.
go back to reference Bowman P, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2012) Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with type 2 diabetes. Diabet Med 29:90–93CrossRef Bowman P, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2012) Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with type 2 diabetes. Diabet Med 29:90–93CrossRef
18.
go back to reference Oram RA, Rawlingson A, Shields BM, Bingham C, Besser REJ, McDonald TJ, Knight BA, Hattersley AT (2013) Urine C-peptide creatinine ratio can be used to assess insulin resistance and insulin production in people without diabetes: an observational study. BMJ 3(12):e003193 Oram RA, Rawlingson A, Shields BM, Bingham C, Besser REJ, McDonald TJ, Knight BA, Hattersley AT (2013) Urine C-peptide creatinine ratio can be used to assess insulin resistance and insulin production in people without diabetes: an observational study. BMJ 3(12):e003193
19.
go back to reference Yilmz Agladioglu S, Sagsak E, Aycan Z (2015) Urinary C-peptide/creatinine ratio can distinguish maturity-onset diabetes of the young from type 1 diabetes in children and adolescents: a single-center experience. Horm Res Paediatr 84(1):54–61CrossRef Yilmz Agladioglu S, Sagsak E, Aycan Z (2015) Urinary C-peptide/creatinine ratio can distinguish maturity-onset diabetes of the young from type 1 diabetes in children and adolescents: a single-center experience. Horm Res Paediatr 84(1):54–61CrossRef
20.
go back to reference Besser REJ, Shepherd MH, McDonald TJ, Shields BM, Knight BA, Ellard S, Hattersley AT (2011) Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-a/hepatocyte nuclear factor 4-a maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 34:286–291CrossRef Besser REJ, Shepherd MH, McDonald TJ, Shields BM, Knight BA, Ellard S, Hattersley AT (2011) Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-a/hepatocyte nuclear factor 4-a maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 34:286–291CrossRef
21.
go back to reference Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve b-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53:250–264CrossRef Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve b-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53:250–264CrossRef
Metadata
Title
Urinary C-peptide creatinine ratio to differentiate type 2 diabetes mellitus from type 1 in pediatric patients
Authors
Wafaa Elzahar
Ahmed Arafa
Amira Youssef
Adel Erfan
Doaa El Amrousy
Publication date
01-07-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Pediatrics / Issue 7/2020
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-020-03606-7

Other articles of this Issue 7/2020

European Journal of Pediatrics 7/2020 Go to the issue